The potent anti-cancer agent doxorubicin (DOX) induces apoptosis of rapidly proliferating cells by inhibiting cellular proteasomes. The aim of the present study was to determine whether DOX modulates the level of expression and function of proteasomes in feline injection-site sarcoma (FISS). Tissue extracts from primary sarcoma lesions and the related healthy subcutis of 18 cats affected by FISS were investigated. Nine of these cats had received neoadjuvantDOXtreatment and nine cats did not receive this therapy. There was enhanced proteasome expression in FISS, but this was not affected by administration of DOX. This finding may account for the low clinical effectiveness of DOX therapy in FISS and provides the rationale for developing new therapeutic protocols aimed at achieving better proteasomal inhibition in FISS and other tumours that respond poorly to DOX therapy

Proteasomes are not a target for doxorubicin in feline injection-site sarcoma

CERRUTI, Fulvia;MARTANO, Marina;MORELLO, Emanuela Maria;BURACCO, Paolo;CASCIO, Paolo
2010-01-01

Abstract

The potent anti-cancer agent doxorubicin (DOX) induces apoptosis of rapidly proliferating cells by inhibiting cellular proteasomes. The aim of the present study was to determine whether DOX modulates the level of expression and function of proteasomes in feline injection-site sarcoma (FISS). Tissue extracts from primary sarcoma lesions and the related healthy subcutis of 18 cats affected by FISS were investigated. Nine of these cats had received neoadjuvantDOXtreatment and nine cats did not receive this therapy. There was enhanced proteasome expression in FISS, but this was not affected by administration of DOX. This finding may account for the low clinical effectiveness of DOX therapy in FISS and provides the rationale for developing new therapeutic protocols aimed at achieving better proteasomal inhibition in FISS and other tumours that respond poorly to DOX therapy
2010
143
164
172
http://www.elsevier.com/wps/find/journaldescription.cws_home/623050/description#description
Doxorubicin; Feline injection-site sarcoma; Proteasome; Proteasome inhibitor
Cerruti, Fulvia; Martano, Marina; Morello, Emanuela Maria; Buracco, Paolo; Cascio, Paolo
File in questo prodotto:
File Dimensione Formato  
j comp path 2010.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 365.11 kB
Formato Adobe PDF
365.11 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
529486 j comp pathol 10.pdf

Open Access dal 01/01/2012

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 443.03 kB
Formato Adobe PDF
443.03 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/87941
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact